A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer

Exclusion Criteria

• •Previously received targeted therapy of the metastatic renal cell carcinoma (such as sunitinib, Sorafenib)
• •Past or suffering from other cancer, but other than cure basal cell carcinoma and cervical carcinoma in situ
• •Participated in other clinical trials within four weeks
• •A variety of factors that affect the oral medication (such as inability to swallow, gastrointestinal resection, chronic diarrhea and intestinal obstruction)
• •Known brain metastases, spinal cord compression, cancer, meningitis, or screening CT or MRI examination revealed brain or leptomeningeal disease
• •Patients with hypertension (systolic blood pressure\> 140 mmHg, diastolic blood pressure\> 90 mmHg). Patients with more than Class I, myocardial ischemia or myocardial infarction, arrhythmia (including QT interval ≥ 440ms) and class I heart failure.
• •Urine protein ≥ + + and confirmed the 24-hour urinary protein\>1.0 g
• •Coagulopathy with bleeding tendency (such as active peptic ulcer) or are receiving thrombolytic or anticoagulant therapy
• •Previous hyperactivity / venous thromboembolic events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis and pulmonary embolism
• •The preexisting abnormal thyroid function, even in the case of medication still can not be maintained within the normal range
• •With a history of abuse of psychotropic drugs or mental disorders
• •Patients with Hepatitis B or Hepatitis C
• •History of immunodeficiency, including HIV testing positive or suffering from acquired, congenital immunodeficiency disease, or a history of organ transplantation